Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-328.94M | $-2.04 |
| 2024 | $0.00 | $-255.86M | $-2.32 |
| 2023 | $0.00 | $-192.41M | $-2.42 |
| 2022 | $0.00 | $-140.24M | $-2.26 |
| 2021 | $0.00 | $-72.27M | $-1.85 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-0.57 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.52 vs $-0.55beat
- Tue, May 5$-0.53 vs $-0.53beat
- Tue, Feb 17$-0.55 vs $-0.51miss
- Fri, Nov 7$-0.50 vs $-0.54beat
- Tue, Aug 5$-0.53 vs $-0.55beat
- Tue, May 6$-0.52 vs $-0.56beat
Estimates and results for COGT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
COGThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·2d ago·Neutral
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - News (RSS)seekingalpha·5d ago·Neutral
Cogent Biosciences reports Q2 results
View source ↗